In this episode, made possible through an educational grant from Sandoz Canada, Dr. George Zhanel discusses the latest developments in antimicrobial stewardship, focusing on IV Amox Clav, its clinical applications, safety profile, and the Canadian Leadership on Antimicrobial Real-Life Usage Registry (CLEAR). Gain insights into optimizing antibiotic use and future prospects in antimicrobial development.
Key Topics:
- IV Amox Clav clinical applications
- Canadian Leadership on Antimicrobial Usage Registry (CLEAR)
- Antibiotic stewardship strategies
- Future developments in antimicrobial agents
Chapters:
00:00 Introduction and Guest Credibility
01:47 Introduction of Dr. George Zhanel and his background
02:41 The journey into IV Amox Clav and its significance
03:21 Overview of the CLEAR registry and its purpose
06:18 Findings from the CLEAR study on IV Amox Clav usage
07:57 Clinical indications and safety profile of IV Amox Clav
10:58 De-escalation and appropriate use of IV Amox Clav
12:34 Use in bacteremia and various infections
13:35 Side effects and safety data of IV Amox Clav
15:02 Dosing strategies and renal adjustments
17:29 Beta-lactamase inhibitors and future antimicrobial development
20:16 Future prospects for new antibiotics in Canada
23:13 Canadian Antimicrobial Resistance Alliance (CARA) and involvement
25:53 Case examples and clinical decision-making in pneumonia and skin infections
31:09 Closing remarks and appreciation for the audience
Resources:
Canadian Leadership on Antimicrobial Real-Life Usage Registry (CLEAR) - https://www.clearregistry.ca
Canadian Antimicrobial Resistance Alliance (CARA) - https://www.cara.ca
Meropenem Vaborbactam - https://www.meropenem.com
Ceftazidime-Avibactam - https://www.ceftazidime-avibactam.com
Guest Links:
LinkedIn - https://www.linkedin.com/in/george-zhanel
Twitter - https://twitter.com/GeorgeZhanel
